Dr Katie FineganMRPharmS

Lecturer in Cancer Biology and Therapy

Full contact details
View graph of relations

Overview

My research group investigates the mechanisms by which mitogen-activated protein kinases (MAPK) regulate cancer biology and therapeutic response.  Using a combination of established pharmacological inhibitors, novel and exclusive pre-clinical mouse models, human samples and in vivo techniques, my group’s central aim is to translate findings at the molecular level into valid therapeutic avenues and/or biomarkers of cancer progression and therapy response. 

Ongoing projects

  • Creating novel ERK5 inhibitors for the treatment of Triple Negative Breast Cancer (TNBC) (CRUK Small Moleucle Award)
  • Validation of a novel immunomodulatory approach to the treatment of Triple Negative Breast Cancer (MRC CiC)
  • Understanding MAPK-driven responses to radiotherapy in TNBC (PhD student, self-funded)
  • Understanding how ERK5 acts as an essential conduit for inflammatory responses during tumour growth, progression and therapy response (Friends of Rosie and British Lung Foundation awards)
  • Validating novel therapeutics that target cancer-associated inflammation (Astex Pharmaceuticals)
  • Delineating MAPK-driven macrophage responses during wound healing (MRC DTP Studentship)
  • Developing imaging biomarkers of tumour progression and treatment response in breast cancer and skin cancer (collaboration with the CRUK Cancer Imaging Centre, Manchester/Cambridge)
  • Characterising how ERK5 promotes metastatic spread of breast cancer (collaboration with the CRUK Cancer Imaging Centre, Manchester/Cambridge)

 

Areas of expertise

Research Networks and Beacons

Related information